Carbohydrate Biology, Glycolysis, and Metabolic Regulation - Comprehensive Notes

Proteoglycans and extracellular matrix (ECM)

• Proteoglycans vs glycoproteins
  • Major difference: proteoglycans do not contain branched glycan units; many have glycosaminoglycans (GAGs) linked to a core protein.
• Serglysin
  • Small proteoglycan with a core protein containing serine and glycine units; contains chondroitin sulfate in some cases.
  • Question raised: what is serglysin? composition involves alternating Ser-Gly units with sulfate groups.
• Collagen and proteoglycans
  • Collagen is a proteoglycan-containing molecule with GAGs attached.
  • Structure is complex and not fully covered here; focus is on functional role.
• Localization and function of proteoglycans
  • Often located outside the cell or have extracellular domains extending outside the membrane.
  • They interact with other proteins to form a stable extracellular matrix (ECM).
  • ECM is tissue-specific, e.g., liver vs eye, providing organ-specific signaling and selective molecular entry via receptors.
• ECM–cell signaling
  • ECM components bind receptors on cell surfaces to trigger signal transduction.
  • The ECM above the lipid bilayer interacts with cytoskeleton to stabilize cell–cell and cell–matrix contacts.
• Key proteoglycans and glycans (examples)
  • Syndecan: transmembrane proteoglycan with intracellular, transmembrane, and extracellular domains; extracellular portion bears GAGs like heparan sulfate and dermatan sulfate.
  • Interactions: syndecan can bind fibronectin; fibronectin interacts with integrins to coordinate signaling across the ECM.
  • Other proteoglycans mentioned: decorin (with chondroitin sulfate and dermatan sulfate), versican (non-branched glycans attached to core protein).
• Functional interactions in ECM
  • Fibronectin contains basic amino acids (e.g., lysine, asparagine) and interacts with sulfate groups on proteoglycans, contributing to ECM stability.
  • The ECM provides structural support and mediates signals to other cells, enabling intercellular communication and organ-specific tissue architecture.
• Practical implications
  • ECM composition underlies tissue-specific signaling and receptor binding; disruptions can affect tissue integrity and signaling pathways.

Carbohydrate biology in medicine and pharmacology (applied concepts)

• Transition state concept in enzymes
  • Enzymes go through a transition state when binding substrates; inhibitors can mimic or stabilize this state to achieve high affinity.
  • Examples: transition-state inhibitors; some ACE inhibitors (e.g., enalapril) target enzyme–substrate interactions to prevent catalysis.
• Neuraminidase inhibitors and antivirals
  • Tamiflu (oseltamivir) and Relenza (zanamivir) inhibit neuraminidase, an enzyme required for budding/release of influenza virions.
  • Neuraminidase function: removes sialic acid from glycoproteins, facilitating viral release.
• Gaucher’s disease and serizyme
  • Serizyme refers to an enzyme used to compensate for deficiency in glucocerebrosidase ( Gaucher’s disease); recombinant enzyme production discussed (e.g., plant-based expression).
• Glycopeptide antibiotics
  • Vancomycin inhibits synthesis of bacterial cell wall peptidoglycan, used in antibiotic-resistant infections.
• Glycoconjugate vaccines and cancer targets
  • Vaccines combining polysaccharides with toxins/proteins (glycoconjugates) enhance immunogenicity.
  • Examples include meningococcal and pneumococcal glycoconjugates; vaccines such as Prevnar (Streptococcus pneumoniae) are discussed.
  • GM2 ganglioside-based vaccine strategies aim to trigger immune responses against cancer cells carrying GM2.
• Other carbohydrate-based therapeutics and research probes
  • GCS-100 and PI-88: sugar-based inhibitors targeting selectins or angiogenesis pathways.
  • Staphyx: vaccine protein linked to bacterial sugar aimed at Staphylococcus aureus infection.
  • Hemophilus influenzae type b glycoconjugate; Neisseria meningitidis glycoconjugates; Salmonella typhimurium VI polysaccharide were cited as examples of glycoconjugate vaccines.
• Practical takeaway
  • Carbohydrate chemistry and glycoconjugates underpin many vaccines, therapeutics, and diagnostic tools; understanding their basic biology helps pharmacists interpret medicinal agents and disease mechanisms.

Glycolysis: localization, purpose, and overall flow

• Cellular location and context
  • Glycolysis occurs in the cytoplasm of cells (including prokaryotes and eukaryotes); RBCs lack mitochondria and rely exclusively on glycolysis for energy.
  • Some texts have historically claimed glycolysis in mitochondria; contemporary teaching emphasizes cytosolic glycolysis.
• Energy yield overview (per glucose)
  • Net ATP from glycolysis: $2\;ATP$ via substrate-level phosphorylation; NADH produced: $2\;NADH$.
  • Linking glycolysis to TCA and oxidative phosphorylation yields much more ATP overall; the guide notes the net energy potential when fully oxidized: up to $\approx 38$ ATP per glucose in prokaryotes; typically 30–32 ATP in eukaryotes due to transport costs.
• Primer: substrate-level phosphorylation and redox
  • Substrate-level phosphorylation produces ATP directly in glycolysis (and TCA).
  • NAD+ is reduced to NADH in glyceraldehyde-3-phosphate dehydrogenase step; NADH later contributes to oxidative phosphorylation for additional ATP.
• Glucose uptake and phosphorylation
  • Glucose is transported into cells by facilitative transporters (GLUTs); GLUT family includes many members (e.g., GLUT4 frequently discussed for insulin-responsive tissues; the lecturer mentions GLUT4 in liver and up to 12 GLUTs total, noting a common confusion with GLUT numbers).
  • Initial phosphorylation traps glucose inside the cell as glucose-6-phosphate (G6P).
• Hexokinase vs glucokinase
  • Hexokinase: broad specificity (can phosphorylate multiple hexoses). Km ≈ $0.03\ \mathrm{mM}$; active at low glucose levels.
  • Glucokinase (in liver and pancreas): high Km ≈ $5\ \mathrm{mM}$; highly specific for glucose; active at higher glucose concentrations; acts as a glucose sensor and helps regulate insulin release.
  • Clinically relevant implication: hexokinase is inhibited by high glucose levels; glucokinase predominates in liver at high glucose to support glycolysis and glycogen synthesis. The lecturer notes this distinction and suggests mnemonic: hexokinase low Km, glucokinase high Km.
• Key early glycolysis steps (glucose → fructose-6-phosphate/ fructose-1,6-bisphosphate)
  • Glucose phosphorylation: $\text{glucose} \xrightarrow{\text{HK/GK}} \text{glucose-6-phosphate}$
  • Isomerization: $\text{glucose-6-phosphate} \rightleftharpoons \text{fructose-6-phosphate}$ via phosphoglucose isomerase.
  • Commitment step: phosphorylation of fructose-6-phosphate to fructose-1,6-bisphosphate by $\text{PFK-1}$, consuming one ATP.
  • Fructose-1,6-bisphosphate is then split by $\text{aldolase}$ into dihydroxyacetone phosphate (DHAP) and glyceraldehyde-3-phosphate (G3P).
• Isomerization and fate of triose phosphates
  • DHAP and G3P are interconvertible via $\text{triose phosphate isomerase}$; only G3P continues in the main glycolytic pathway.
• Redox and energy-yielding steps in glycolysis
  • G3P dehydrogenase step: $\text{G3P} + \text{NAD}^+ + \text{Pi} \rightarrow \text{1,3-bisphosphoglycerate} + \text{NADH} + H^+$
  • Inorganic phosphate source: cytosolic Pi; GAPDH step also produces NADH (reduced power).
  • Substrate-level phosphorylation steps:
  • 1,3-bisphosphoglycerate to 3-phosphoglycerate: ATP generated via phosphoglycerate kinase.
  • 2-phosphoglycerate to phosphoenolpyruvate (PEP) via enolase.
  • PEP to pyruvate via pyruvate kinase: another ATP generated.
• End products and net yield in glycolysis
  • Per glucose: net ATP from substrate-level phosphorylation = $2\;ATP$; NADH produced = $2\;NADH$ (from the GAPDH step).
  • The two NADH can yield additional ATP via oxidative phosphorylation (e.g., each NADH ~ 3 ATP under typical mitochondrial coupling assumptions).
• Moonlighting enzymes in glycolysis
  • Phosphoglucoisomerase and other glycolytic enzymes can have secondary (moonlighting) roles, including non-metabolic functions such as neural survival factors or cell signaling, beyond their catalytic glycolytic activity (neuroleukin/autocrine motility factor/DMM mentioned).
• Glycerol, fructose, and alternative entry routes
  • Glycerol: glycerol → glycerol-3-phosphate (via glycerol kinase, consumes ATP) → dihydroxyacetone phosphate via glycerol-3-phosphate dehydrogenase → DHAP enters glycolysis.
  • Fructose metabolism:
  • In glycolysis, fructose can be phosphorylated to fructose-6-phosphate or enter as fructose-1-phosphate in the liver, depending on tissue.
  • After fructose-1-phosphate formation, aldolase splits to DHAP and GAP; glyceraldehyde is phosphorylated to GAP and enters glycolysis.
  • Fructose discussion in the lecture includes potential links to fatty liver disease with high-fructose intake; a cautionary note on metabolic consequences.
• Galactose metabolism (brief)
  • Galactose is converted to galactose-1-phosphate and then to UDP-galactose; UDP-glucose formation enabled by UDP-glucose pyrophosphorylase (enzyme activity may be defective in certain galactosemia variants).
  • UDP-glucose can be converted to glucose-1-phosphate and then to glucose-6-phosphate to enter glycolysis.
• Glycerol metabolism details (deeper look)
  • Glycerol entry into glycolysis is via glycerol kinase to glycerol-3-phosphate; glycerol-3-phosphate dehydrogenase then forms DHAP; DHAP enters the glycolytic pathway as above.
• Transport and regulation of glycolysis in vivo
  • Glucose transporters (GLUT family) mediate entry of glucose into cells; the lecture highlights GLUT4 in liver (note: canonical liver transporter is typically GLUT2; the lecture may reflect common teaching variations or a specific context);
  • Once inside, glucose is rapidly phosphorylated to G6P, keeping glucose levels in cytosol low and driving glycolysis forward.
• Regulation of glycolysis by energy state
  • Key regulators: ATP and ADP/AMP balance the glycolytic flux.
  • For phosphofructokinase-1 (PFK-1): ATP binding inhibits activity at high energy (negative feedback) while AMP binding stimulates at low energy (positive feedback).
  • The enzyme shows allosteric regulation with a sigmoid response to ATP/AMP depending on the cellular energy state.
• Special case: pyruvate kinase (PK) and mitochondrial (M2) isoforms
  • PK exists in liver (L) and erythrocyte (RBC) forms; muscle and proliferating cells express PKM1/PKM2 isoforms.
  • PKM2 in proliferating cells can translocate to the nucleus and act as a kinase using phosphoenolpyruvate (PEP) as phosphate donor, contributing to oncogenic signaling and proliferation.

Pyruvate fate, acetyl-CoA entry, and the TCA cycle

• Pyruvate to acetyl-CoA conversion
  • Pyruvate dehydrogenase (PDH): $\text{pyruvate} + \text{CoA} + \text{NAD}^+ \rightarrow \text{acetyl-CoA} + \mathrm{CO}_2 + \text{NADH} + H^+.$
  • This reaction occurs in mitochondria and links glycolysis to the TCA cycle.
• Pyruvate and anaplerosis
  • Pyruvate can be carboxylated to oxaloacetate via pyruvate carboxylase, providing oxaloacetate for gluconeogenesis or TCA cycle replenishment when needed.
• Entry into the TCA cycle
  • Acetyl-CoA combines with oxaloacetate to form citrate (via citrate synthase).
  • Citrate isomerized to isocitrate by aconitase; isocitrate is oxidatively decarboxylated to alpha-ketoglutarate with formation of NADH; a second NADH is generated in subsequent steps.
  • Alpha-ketoglutarate undergoes oxidative decarboxylation to succinyl-CoA with another NADH formed.
  • Succinyl-CoA is converted to succinate, generating GTP (or ATP) via substrate-level phosphorylation.
  • Succinate is converted to fumarate (FADH2 produced by succinate dehydrogenase, which contains covalently bound FAD).
  • Fumarate is hydrated to malate; malate is oxidized to oxaloacetate, generating another NADH.
• Overall per acetyl-CoA in TCA
  • Each turn yields: 3 NADH, 1 FADH2, 1 GTP (or ATP).
  • For two acetyl-CoA per glucose, this doubles to: 6 NADH, 2 FADH2, 2 GTP.
• Fluoroacetate toxicity as a metabolic poison (illustrative example)
  • Fluoroacetate combines with oxaloacetate to form fluorocitrate, inhibiting aconitase and blocking the TCA cycle.
  • LD50 for fluoroacetate is about $0.2\ \mathrm{mg\,kg^{-1}}$ (acute toxicity).
• Arsenate toxicity and glycolysis disruption
  • Arsenate can substitute for phosphate to enter glycolytic steps; it forms an unstable acyl-phosphate intermediate that destabilizes ATP generation, reducing substrate-level phosphorylation efficiency.
• Substrate-level phosphorylation in TCA
  • Succinyl-CoA synthetase hydrolysis yields GTP (or ATP) directly, representing substrate-level phosphorylation in the TCA cycle.

ATP yield and energy accounting (glucose oxidation)

• Summary of ATP generation pathways
  • Glycolysis (cytosol): net $2\;ATP$ + $2\;NADH$ (which can yield up to 6 ATP per glucose in mitochondria, depending on shuttle).
  • Pyruvate oxidation: 2 NADH → up to 6 ATP.
  • TCA cycle: per glucose, 6 NADH (×3 ATP each = 18 ATP), 2 FADH2 (×2 ATP each = 4 ATP), and 2 GTP (≈ 2 ATP).
  • Total theoretical yield: up to about $38\ \text{ATP}$ per glucose in prokaryotes; in eukaryotes, typically ~30–32 ATP due to shuttling costs (e.g., NADH from glycolysis transported into mitochondria).
• Practical caveat on energy accounting
  • Some energy is expended transporting substrates (e.g., pyruvate/aspartate shuttle) across mitochondrial membranes; thus the practical yield in mammals is often 30–32 ATP per glucose.
• Efficiency considerations
  • The overall energy extraction from glucose is about $\approx 62\ \mathrm{kJ/mol}$ usable energy out of the theoretical energy content; glycolysis and oxidation are around 30–35% efficient, with the rest dissipated as heat or lost in transport processes.

Regulation and metabolic control (concepts and examples)

• Allosteric regulation of key enzymes
  • Phosphofructokinase-1 (PFK-1): activated by AMP and ADP (low energy), inhibited by ATP (high energy); complex allosteric behavior with multiple binding sites.
  • ATP/AMP balance acts as a master regulator of glycolytic flux; high ATP slows glycolysis, high ADP/AMP drives it.
• Moonlighting roles of glycolytic enzymes
  • Phosphoglucoisomerase, among others, has non-metabolic roles; secreted forms like neuroleukin act as neuronal survival factors; other forms influence tumor cell migration and differentiation.
• Regulation by energy state and signaling
  • When cellular ATP is high, glycolysis and TCA are downregulated; when NADH or ATP levels are high, the oxidation of NADH and production of ATP via oxidative phosphorylation is favored.
• Hypoxia and glycolysis (HIF pathway)
  • Under normoxia: HIF-1α is hydroxylated by prolyl hydroxylases and targeted for proteasomal degradation via the VHL complex.
  • Under hypoxia: HIF-1α is stabilized, dimerizes with HIF-1β, translocates to the nucleus, binds hypoxia response elements, and upregulates glycolytic genes (e.g., hexokinase, lactate dehydrogenase, glucose transporters, lactate transporters).
  • This shifts metabolism toward glycolysis and lactate production when oxygen is limited.

Metabolic fate choices and disease-related contexts

• Lactate production and the Cori cycle
  • In fast exercise, pyruvate is reduced to lactate in muscles by lactate dehydrogenase; lactate travels to the liver and is reconverted to glucose via gluconeogenesis.
• Cancer metabolism (the Warburg effect)
  • Many cancer cells preferentially use glycolysis even in the presence of oxygen to generate biomass precursors and ATP, supporting rapid proliferation.
  • Glucose uptake is often elevated; PET imaging with 18F-fluorodeoxyglucose (FDG) exploits increased uptake to detect tumors.
• PET imaging and glucose uptake
  • FDG behaves like glucose; tumors show higher uptake and positron emission, enabling diagnostic imaging.

Fructose, galactose, and glycerol metabolism (alternative sugar fates)

• Fructose metabolism
  • In the liver, fructose is phosphorylated to fructose-1-phosphate (via ketohexokinase, fructokinase), then split into DHAP and GAP via aldolase B.
  • DHAP and GAP feed into glycolysis; glyceraldehyde can be phosphorylated to GAP and proceed through the pathway.
  • Fructose metabolism and rapid intake can contribute to fatty liver disease in some contexts due to lipogenic flux.
• Galactose metabolism (galactosemia risks)
  • Galactose is converted to galactose-1-phosphate and then to UDP-galactose; UDP-glucose formation requires the enzyme UDP-glucose pyrophosphorylase.
  • Defects in this pathway (e.g., GALT deficiency) lead to galactose accumulation with potential cataracts and neurological consequences.
• Glycerol metabolism
  • Glycerol from fat breakdown is phosphorylated to glycerol-3-phosphate and then oxidized to DHAP, entering glycolysis.

Red blood cells (RBCs) and glycolysis

• RBC energy and redox balance
  • RBCs rely on glycolysis as they lack mitochondria for oxidative phosphorylation.
  • NADH produced in glycolysis can support NADPH production via pentose phosphate pathway, which helps maintain reduced glutathione (GSH) and protect against oxidative damage.
  • NADPH is crucial for reducing oxidized glutathione (GSSG) back to GSH, maintaining RBC integrity.
• Physiological significance
  • RBCs use glycolysis for ATP to power ion pumps and maintain cell shape and function; the process is tightly linked to redox balance and antioxidant defense.

Energy and metabolism in context: RBCs, cancer, and diagnostics

• Cancer metabolism and glycolysis (revisited)
  • Cancer cells may upregulate glycolysis (aerobic glycolysis) to support rapid growth and biomass production; HIF signaling contributes to this shift in hypoxic tumor microenvironments.
• Diagnostic and therapeutic implications
  • Glycolytic flux and glucose uptake can be probed with imaging (e.g., FDG-PET) to detect cancers and monitor treatment response.
• Practical takeaway for pharmacists
  • Understanding glycolysis, gluconeogenesis, and carbohydrate metabolism helps in predicting drug interactions, metabolic disease risks (e.g., fatty liver with high-fructose intake), and interpreting metabolic biomarkers.

Quick reference: key equations and numerical anchors

• Enzyme-catalyzed reactions (selected)
  • Glycolysis initiation:
  • $\text{Glucose} + \text{ATP} \rightarrow \text{Glucose-6-phosphate} + \text{ADP}$
  • $\text{G6P} \rightleftharpoons \text{F6P}$ via phosphoglucose isomerase
  • Commitment step:
  • $\text{F6P} + \text{ATP} \rightarrow \text{F-1,6-BP} + \text{ADP}$ via $\text{PFK-1}$
  • Cleavage:
  • $\text{F-1,6-BP} \rightarrow \text{DHAP} + \text{GAP}$ via $\text{Aldolase}$
  • GAPDH step (redox):
  • $\text{GAP} + \text{NAD}^+ + \text{Pi} \rightarrow \text{1,3-BPG} + \text{NADH} + H^+$
  • Substrate-level ATP generation steps:
  • $\text{1,3-BPG} + \text{ADP} \rightarrow \text{3-PG} + \text{ATP}$ via $\text{Phosphoglycerate kinase}$
  • $\text{PEP} + \text{ADP} \rightarrow \text{Pyruvate} + \text{ATP}$ via $\text{Pyruvate kinase}$
• Pyruvate oxidation and TCA
  • PDH step:
  • $\text{Pyruvate} + \text{NAD}^+ + \text{CoA} \rightarrow \text{Acetyl-CoA} + \text{CO}_2 + \text{NADH} + H^+$
  • Pyruvate to oxaloacetate (anaplerosis):
  • $\text{Pyruvate} + \text{CO}<em>2 + \text{ATP} \rightarrow \text{Oxaloacetate} + \text{ADP} + \text{P</em>i}$ via $\text{pyruvate carboxylase}$
  • Citric acid cycle (per acetyl-CoA):
  • $\text{Acetyl- CoA} + \text{Oxaloacetate} \rightarrow \text{Citrate}$
  • $\text{Citrate} \rightarrow \text{Isocitrate} \rightarrow \alpha\text{-Ketoglutarate} \rightarrow \text{Succinyl-CoA} \rightarrow \text{Succinate} \rightarrow \text{Fumarate} \rightarrow \text{Malate} \rightarrow \text{Oxaloacetate}$
  • NADH and FADH2 yields in the cycle: 3 NADH, 1 FADH2, 1 GTP per acetyl-CoA
• Overall ATP yield (per glucose, approximate)
  • Glycolysis: $2\;ATP\,+2\;NADH$
  • Pyruvate oxidation: $2\;NADH$
  • TCA (per glucose): $6\;NADH + 2\;FADH_2 + 2\;GTP$
  • Total (prokaryotes): $38\;ATP$; (eukaryotes): typically ~30–32 ATP due to shuttle costs

Notes for exam-style recall

• Distinguish proteoglycans from glycoproteins by branching and GAG content; know serglycin as a short proteoglycan core protein with Ser-Gly repeats.
• Understand the role of syndecan and fibronectin in ECM signaling to the cytoskeleton via integrins.
• Be able to explain transition-state inhibitors and give at least two medicinal examples (e.g., Tamiflu, Relenza) and a protein-targeted example (ACE inhibitors as transition-state–mimicking inhibitors).
• Memorize the key metabolic yields and the overall ATP sum for glucose oxidation and the rationale for differences between prokaryotic and eukaryotic ATP yield.
• Be able to describe how hypoxia shifts metabolism toward glycolysis via HIF and how this relates to cancer metabolism and PET imaging.
• Know the basic entry points of fructose and galactose into glycolysis, and the potential metabolic consequences of high-fructose intake (e.g., fatty liver).
• Recall the roles of arsenate and fluoroacetate as metabolic inhibitors and their specific sites of action in glycolysis and the TCA cycle.
• Review the exact steps of glycolysis in order, including where NADH and ATP are generated, and where key substrates (G6P, F6P, F1,6BP, G3P, 1,3-BPG, 3-PG, 2-PG, PEP) appear.
• Understand RBC energy metabolism and the link between glycolysis, NADPH production, and antioxidant defense (glutathione system).
• Be ready to discuss how insulin release relates to glucokinase activity in liver and pancreas, and why hexokinase and glucokinase differ in kinetics and regulatory roles.